STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] Tharimmune, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Tharimmune (THAR) reported insider activity on a Form 4. A company director reported acquiring 90,000 stock options on 11/03/2025 at an exercise price of $3.075 per share. The options are first exercisable on 11/03/2025 and expire on 11/03/2035.

Following the transaction, the filing lists 190,000 derivative securities beneficially owned. The ownership is marked as Indirect (I), with a footnote referencing relationships among Gravitas Capital LP, Gravitas Capital Partners LLC, and Vincent S. LoPriore. This filing records the insider’s equity-linked position and timing terms.

Positive
  • None.
Negative
  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gravitas Capital LP

(Last) (First) (Middle)
C/O THARIMMUNE, INC.
34 SHREWSBURY AVE.

(Street)
RED BANK NJ 07701

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Tharimmune, Inc. [ THAR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/03/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option $3.075 11/03/2025 A 90,000 11/03/2025 11/03/2035 Common Stock 90,000 $0 190,000 I See footnoe(1)
Explanation of Responses:
1. Gravitas Capital LP is a Delaware limited partnership whose sole general partner is Gravitas Capital Partners LLC. The managing member of Gravitas Partners LLC is Vincent S. LoPriore. As a result, Gravitas Capital LP is deemed to be the indirect owner of the securities held directly by Vincent S. LoPriore. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b) (1) of the Securities Exchange Act of 1934
/s/ Vincent LoPriore 11/05/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Tharimmune (THAR) disclose in this Form 4?

A director reported acquiring 90,000 stock options on 11/03/2025 at an exercise price of $3.075 per share.

What is the exercise price and term of the THAR options?

The options have an exercise price of $3.075, become exercisable on 11/03/2025, and expire on 11/03/2035.

How many derivative securities are held after the transaction?

The filing shows 190,000 derivative securities beneficially owned following the reported transaction.

Is the ownership direct or indirect in this THAR Form 4?

The ownership is listed as Indirect (I) with a footnote explaining relationships among Gravitas Capital LP, Gravitas Capital Partners LLC, and Vincent S. LoPriore.

Did the Form 4 indicate a sale of Tharimmune common stock?

The reported activity relates to stock options acquired; the table shows 90,000 options underlying common stock.

Who signed the THAR Form 4 filing?

It was signed by Vincent LoPriore on 11/05/2025.
Tharimmune Inc

NASDAQ:THAR

THAR Rankings

THAR Latest News

THAR Latest SEC Filings

THAR Stock Data

30.36M
5.03M
17.13%
1.5%
12.08%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRIDGEWATER